Joyce Lo
Associate Director Biogen
Seminars
Wednesday 3rd June 2026
Panel Discussion: How the Industry is Leveraging Spatial Omics for ALS Target Discovery & Biomarkers?
8:30 am
- How is spatial omics transforming our understanding of ALS pathology compared with traditional bulk tissue or single-cell approaches?
- Which emerging ALS targets or molecular pathways have been most compellingly revealed through spatial transcriptomics, proteomics, or multi-omic integration?
- How can spatial omics data be translated into actionable biomarkers for clinical trials, including patient stratification, early detection, or monitoring therapeutic response?
- What are the key technical, analytical, and interpretational challenges in applying spatial omics to human ALS tissue, and how are industry and academia addressing these?
- How do collaborative approaches between pharma, academic centers, and genome institutes accelerate the path from spatial omics discovery to drug development?
- Looking forward, what role will AI and machine learning play in extracting meaningful insights from complex spatial omics datasets in ALS?
Thursday 4th June 2026
A 30,000 Foot View of TDP43 Direct Targeting Strategies – A Thought Experiment
1:30 pm
- Overview of TDP-43 pathology as the central disease hallmark in the majority of ALS patients
- Current therapeutic approaches targeting TDP-43 loss of nuclear function
- Strategies aimed at mitigating toxic gain of function, aggregation, and cytoplasmic mislocalization
- Key lessons from the field, remaining translational challenges, and future directions for TDP-43–targeted therapies
